Kedrion alongside AICE on the 50th Ann. of the first AICE Triennial Conference
The company supports the reading of a scientific study on the role of Factor VIII in the protection of the joints
Kedrion announces the appointment of a new CEO
Val Romberg from the USA, one of the most esteemed managers in the industry
Kedrion supports the 2020 European Hemophilia Consortium Conference
The company renews its commitment alongside the EHC, which continues to support the PARTNERS project
KEDPLASMA GmbH changes its name to Kedrion Biopharma GmbH
Further step towards an even stronger focus on patients in Europe
First and Only US Pediatric human rabies Immune globulin Trial
Kedrion-Kamada Announce Study Met Its Primary Objective
Kedrion-Kamada collaboration, first patient enrolled in the clinical trial
Yet another milestone in the global Kedrion-Kamada collaboration for the development, manufacturing and distribution of a plasma-derived immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). On Aug. 10, 2020 Kamada Ltd. announced that the first patient has been recruited to the Phase 1/2 clinical trial of its anti-SARS-CoV-2 plasma-derived immunoglobulin (IgG) product
Kedrion’s Mother and Child Health campaign for Asia and MEA announced
Details were unveiled during our first televised Regional Distributor Meeting on July 14th-15th
COVID-19. Kedrion partners with Columbia University Irving MC
Kedrion and Columbia University release video statements
ISTH, Kedrion supports symposium on the importance of inhibitor eradication
The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A
Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020
The company reaffirms its commitment to the patient community during the COVID-19 epidemic